JP2024527043A5 - - Google Patents

Info

Publication number
JP2024527043A5
JP2024527043A5 JP2024504950A JP2024504950A JP2024527043A5 JP 2024527043 A5 JP2024527043 A5 JP 2024527043A5 JP 2024504950 A JP2024504950 A JP 2024504950A JP 2024504950 A JP2024504950 A JP 2024504950A JP 2024527043 A5 JP2024527043 A5 JP 2024527043A5
Authority
JP
Japan
Prior art keywords
sequence
seq
variable region
chain variable
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527043A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074284 external-priority patent/WO2023010098A2/en
Publication of JP2024527043A publication Critical patent/JP2024527043A/ja
Publication of JP2024527043A5 publication Critical patent/JP2024527043A5/ja
Pending legal-status Critical Current

Links

JP2024504950A 2021-07-28 2022-07-28 新規多重特異性分子 Pending JP2024527043A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021109028 2021-07-28
CNPCT/CN2021/109028 2021-07-28
CNPCT/CN2022/103725 2022-07-04
CN2022103725 2022-07-04
PCT/US2022/074284 WO2023010098A2 (en) 2021-07-28 2022-07-28 Novel multi-specific molecules

Publications (2)

Publication Number Publication Date
JP2024527043A JP2024527043A (ja) 2024-07-19
JP2024527043A5 true JP2024527043A5 (cg-RX-API-DMAC7.html) 2025-08-04

Family

ID=85088266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504950A Pending JP2024527043A (ja) 2021-07-28 2022-07-28 新規多重特異性分子

Country Status (10)

Country Link
US (1) US20240336686A1 (cg-RX-API-DMAC7.html)
EP (1) EP4377357A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527043A (cg-RX-API-DMAC7.html)
KR (1) KR20240039005A (cg-RX-API-DMAC7.html)
CN (1) CN118055946A (cg-RX-API-DMAC7.html)
AU (1) AU2022319934A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226306A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001328A (cg-RX-API-DMAC7.html)
TW (1) TW202311296A (cg-RX-API-DMAC7.html)
WO (1) WO2023010098A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022063272A1 (en) * 2020-09-28 2022-03-31 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
WO2024153193A1 (en) * 2023-01-18 2024-07-25 Elpiscience (Suzhou) Biopharma, Ltd. Bi-specific molecules targeting sirpa and claudin 18.2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
EP3634484A4 (en) * 2017-06-05 2022-01-12 The Council of the Queensland Institute of Medical Research A COMBINATION OF OR A BI-SPECIFIC BINDING MOLECULE TO AN IMMUNOCONTROL MOLECULE ANTAGONIST AND A RANK-L (NF-κB-LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF
WO2019183266A1 (en) * 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
MX2020013068A (es) * 2018-07-10 2021-03-02 Univ Kobe Nat Univ Corp Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
WO2021003082A1 (en) * 2019-07-03 2021-01-07 Phanes Therapeutics, Inc. Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof
US20210347908A1 (en) * 2019-08-20 2021-11-11 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
EP4081548A4 (en) * 2019-12-24 2024-07-24 LaNova Medicines Limited Anti-sirp? monoclonal antibodies and uses thereof

Similar Documents

Publication Publication Date Title
TWI840386B (zh) 抗間皮素抗體
JP6779299B2 (ja) 抗pd−l1抗体およびその使用
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2021514664A5 (cg-RX-API-DMAC7.html)
JP2021534802A5 (cg-RX-API-DMAC7.html)
JP2024531900A5 (cg-RX-API-DMAC7.html)
JP2025503322A5 (cg-RX-API-DMAC7.html)
AU2019382505B2 (en) Anti-PD-1 antibodies and uses thereof
US20250051467A1 (en) Fap/cd40 binding molecule and medicinal use thereof
US20240002539A1 (en) Multispecific antibodies and uses thereof
WO2020089794A1 (en) Methods of treating cancer
TW202221035A (zh) 抗ilt2抗體及其用途
WO2023040945A1 (zh) 特异性结合pd-1的蛋白及其医药用途
WO2023060277A1 (en) Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
CA3091502A1 (en) Anti-pd-1 antibodies and uses thereof
JP2023550832A5 (cg-RX-API-DMAC7.html)
JP2025503513A5 (cg-RX-API-DMAC7.html)
WO2024114676A1 (zh) Cldn18.2/4-1bb结合蛋白及其医药用途
CN118076638A (zh) 新型抗sirpa抗体
WO2023151661A1 (zh) 免疫缀合物及其用途
WO2024088346A1 (en) Anti-ccr8 antibodies and uses thereof
JP2023525991A5 (cg-RX-API-DMAC7.html)
JP2025517737A5 (cg-RX-API-DMAC7.html)
JP2025513588A5 (cg-RX-API-DMAC7.html)